Not Yet RecruitingNot Applicable

Determinants of Malignant Hypertension Onset and Related Target Organ Damages: the HAMA Biobank

1,000 participantsStarted 2025-08-01

Plain-language summary

The HAMA bank is an initiative aimed at collecting, preparing, and storing biological samples from patients treated for malignant hypertension and included in the HAMA cohort. Conducted under CRB (ISO20387) conditions, this biobank serves as an essential resource for understanding the disease's pathophysiology, as well as for identifying novel biomarkers and therapeutic targets

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients included in the HAMA cohort with the following critera : * Malignant hypertension according to the classic definition (Severe hypertension associated with severe hypertensive retinopathy) * Severe hypertension associated with acute target organ damage due to high blood pressure Exclusion Criteria: * Refusal to participate to the substudy " HAMA bank " * patient on chronic dialysis

What they're measuring

Decipher the mechanisms responsible for the transition from severe to malignant hypertension

Timeframe: At inclusion and 6 month

Trial details

NCT IDNCT06629363

SponsorCentre Hospitalier de PAU

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2036-04-01

Contact for this trial

Alice SERIS

0559726997 alice.seris@ch-pau.fr

View on ClinicalTrials.gov More Malignant Hypertension trials